Total Funding
67
3
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
743505
ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies.
- Camilo Colaco: Founder and Chief Scientific Officer
About the Company
ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies.
ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells.
ImmBio's lead
programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.
